Navigation Links
Sofinnova Raises $500 Million Biotech Venture Fund
Date:7/23/2014

MENLO PARK, Calif., July 23, 2014 /PRNewswire/ -- Sofinnova Ventures, a Menlo Park based investment firm, today announced the closing of Sofinnova Venture Partners IX, L.P. at the hard cap of $500 million and in excess of the initial fund target of $425 million.

Sofinnova focuses exclusively on helping entrepreneurs build successful biotechnology companies. Consistent with recent funds, SVP IX will provide capital primarily to companies with promising later stage clinical programs, along with select investments in earlier stage opportunities. Investments will focus on developing specialty pharmaceuticals and orphan disease products. Sofinnova intends to continue the firm's successful strategy of sourcing investments in both the United States and Europe.

"We value the support that our returning limited partners and new investors have shown for our strategy and the Sofinnova team," commented Jim Healy, General Partner, Sofinnova. "Sofinnova is proud to partner with talented entrepreneurs who are focused on developing innovative medicines that can positively impact patient care. We remain committed to working with our collective network to identify and develop important new drugs, build successful companies, and continue to generate significant returns for our investors."

Sofinnova recent IPOs and exits include Labrys (acquired by Teva), ZS Pharma (IPO, ZSPH), Versartis (IPO, VSAR), Aerie (IPO, AERI), Tesaro (stock sale, TSRO), SARcode (acquired by Shire), NextWave (acquired by Pfizer), Intellikine (acquired by Takeda), Hyperion (IPO, HPTX), Durata (IPO, DRTX), Amarin (stock sale, AMRN),  Vicept (acquired by Allergan) and Preglem (acquired by Gedeon Richter).

The partners of SVP IX are Srini Akkaraju, MD, PhD, Jim Healy, MD, PhD, Anand Mehra, MD, Mike Powell, PhD, Lars Ekman, MD, PhD, David Kabakoff, PhD and Jay Shepard.

About Sofinnova Ventures

Sofinnova Ventures has over 40 years of experience building life science companies into market leaders. With $1.8 billion in committed capital, the firm applies capital and expertise to take companies from inception to exit. Sofinnova's investment team of MDs, PhDs and seasoned executives has significant scientific, operational and strategic experience, and specializes in financing clinical therapeutics. Our team partners with entrepreneurs to build successful companies, advance medicine and address patients' unmet medical needs.

Sofinnova is headquartered in Menlo Park, CA with offices in La Jolla, CA and Dublin, Ireland. www.sofinnova.com.

Contact Information:
Jennifer James
Partner – Investor Relations and Marketing
Sofinnova Ventures
(650) 681-8429; Jennifer@sofinnova.com

Logo - http://photos.prnewswire.com/prnh/20130724/SF52046LOGO-b


'/>"/>
SOURCE Sofinnova Ventures
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Edico Genome Raises $10 Million in Series A Financing to Commercialize DRAGEN Chip to Overcome Sequencing Data Analysis Bottleneck
2. Tute Genomics Raises $1.5M for Cloud-based Genome Analytics & Machine-learning for Gene Discovery
3. Curoverse Raises $1.5 Million to Build Open Source Platform for Genomic and Biomedical Big Data
4. The Holistic Sanctuary Raises Alarm About Teenage Drug Addiction
5. Immune Design Raises Up to $49 Million Series C Financing
6. Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care
7. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
8. Advanced Animal Diagnostics Raises $6 Million for On-farm Diagnostics
9. OriGene Technologies Raises $21.3 Million in Series C Funding
10. Z Trim Holdings Announces Conclusion of Successful Warrant Exercise Program: Raises $2.195 Million
11. Strand Raises Series B From Burrill & Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):